Galenica Ag · SIX:GALE
Galenica — Investor Presentation (January 2023)
87 slides from Galenica's investor presentation, January 2023
Slide 1: Investor Presentation
Galenica Group Investor Presentation August 2022 (updated January 2023) Galenica – Health and wellbeing are at the heart of what we do.
Slide 2: Table of contents
About Galenica Market environment Business performance Governance Sustainability Outlook Table of contents 3 About Galenica 28 Market environment 40 Business performance 61 Governance 71 Sustainability 80 Outlook 18/01/23 2
Slide 3: About Galenica
About Galenica Galenica – Health and wellbeing are at the heart of what we do. 3
Slide 4: Galenica in figures
About Galenica Market environment Business performance Governance Sustainability Outlook Galenica in figures1) Net sales EBIT adjusted2) Leading healthcare Employees provider in Switzerland (Headcount) in million CHF in million CHF 368 own pharmacies > 7,200 Galenica Group Galenica Group Debt covera
Slide 5: Building the leading Swiss healthcare platform over 90 years
About Galenica Market environment Business performance Governance Sustainability Outlook Building the leading Swiss healthcare platform over 90 years Acquisition Foundation of Joint IPO Galenica as a Venture wholesaler Joint Venture Acquisition Strategy to Acquisition engage in the entire Swiss Acqu
Slide 6: Switzerland's leading fully integrated healthcare provider
About Galenica Market environment Business performance Governance Sustainability Outlook Switzerland's leading fully integrated healthcare provider Largest network of Wide range of services for pharmacies in Switzerland patients and professional with over 500 pharmacies, service providers online and
Slide 7: Customer promise
About Galenica Market environment Business performance Governance Sustainability Outlook Customer promise We support people at every stage of life on their journey towards health and well-being. With personal and expert advice and a unique range of products and services. Anytime and anywhere in Swit
Slide 8: What we do
About Galenica Market environment Business performance Governance Sustainability Outlook What we do Vision Health and wellbeing are at the heart of what we do. They are the reason we give our best every day. Values We build We show Together, we We act as We participate with trust respect are stronge
Slide 9: Business model
About Galenica Market environment Business performance Governance Sustainability Outlook Business model Vision Customer promise Health and wellbeing are at the We support people at every stage of life on their heart of what we do. They are the journey towards health and wellbeing. reason we give our
Slide 10: Strategic programmes
About Galenica Market environment Business performance Governance Sustainability Outlook Strategic programmes Market orientation Internal organisation Omni-Channel Care Professionals Efficiency Transformation − Best customer experience − First point of contact for − First-choice partner for − Simple
Slide 11: Our Business Units: Strong on the market
About Galenica Market environment Business performance Governance Sustainability Outlook Our Business Units: Strong on the market Products & Care Logistics & IT Retail (B2C) Professionals (B2B) Local Pharmacies Pharmacies at Home Products & Brands Services for Wholesale Logistics & Professionals IT
Slide 12: Our Business Areas
About Galenica Market environment Business performance Governance Sustainability Outlook Our Business Areas1) Net sales EBIT2) in million CHF in million CHF 3,835 213 Products & Care Logistics & IT Net sales EBIT2) Net sales EBIT2) in million CHF in million CHF in million CHF in million CHF 1,908 15
Slide 13: Local pharmacies: Three largest pharmacy chains in Switzerland
About Galenica Market environment Business performance Governance Sustainability Outlook Local pharmacies: Three largest pharmacy chains in Switzerland Key takeaways Largest branded pharmacy network by number of pharmacies − Largest pharmacy network offers broad product in Switzerland 1 range, inclu
Slide 14: Local pharmacies: Broad range of product and service offerings
About Galenica Market environment Business performance Governance Sustainability Outlook Local pharmacies: Broad range of product and service offerings Amavita and Sun Store product offering Service offerings in local pharmacies in % of sales1 (selection) Primary Care Health Checks Prescription medi
Slide 15: Local pharmacies: Always available where our customers are
About Galenica Market environment Business performance Governance Sustainability Outlook Local pharmacies: Always available where our customers are Widely spread pharmacy network covers every Demonstrated M&A track record with an average of Region in Switzerland 8 pharmacies acquired and 6 net pharm
Slide 16: Pharmacies at home: Mail order pharmacies and home care services
About Galenica Market environment Business performance Governance Sustainability Outlook Pharmacies at home: Mail order pharmacies and home care services Key takeaways Total Retail Net Sales (2022) − Business area covers both home care (Bichsel & Mediservice) and Mail-order pharmacies (Mediservice &
Slide 17: Pharmacies at home: Bichsel home care services
About Galenica Market environment Business performance Governance Sustainability Outlook Pharmacies at home: Bichsel home care services for over 9,000 active patients across Switzerland − Improve quality of life, e.g. enhanced mobility, continuation in familiar setting − Efficient provision of servi
Slide 18: Pharmacies at home: Mediservice as market leading mail-order pharmacy
About Galenica Market environment Business performance Governance Sustainability Outlook Pharmacies at home: Mediservice as market leading Mail-order pharmacy in Switzerland1 Market leading mail-order Market Share Mail-order pharmacies1 pharmacy in Switzerland1 70% Specialty pharmacy focused on pati
Slide 19: Products & Brands: Strong brands for the Swiss Consumer Healthcare Market
About Galenica Market environment Business performance Governance Sustainability Outlook Products & Brands: Strong brands for the Swiss Consumer Healthcare Market Key takeaways − Leading position1) in the Swiss consumer healthcare market (CHC) Selected − Preferred Consumer Health partner for Swiss o
Slide 20: Products & Brands: Verfora market share in Swiss CHC market
About Galenica Market environment Business performance Governance Sustainability Outlook Products & Brands: Strong brands for the Swiss Consumer Healthcare Market Verfora market share in Swiss CHC market1 Market share of main OTC product categories of Verfora OTC products 12.9% market share CHF 224.
Slide 21: Products & Brands: Proven M&A track record
About Galenica Market environment Business performance Governance Sustainability Outlook Products & Brands: Proven M&A track record as key driver for market share growth Verfora growth strategy − Big OTC brands Acquisition Acquisition Hedoga Group Dr. Wild − Emerging platforms Distribution 10.0% com
Slide 22: Services for Professionals: High quality services
About Galenica Market environment Business performance Governance Sustainability Outlook Services for Professionals: We support healthcare professionals with high quality services − Lifestage Solutions develops and operates a fully integrated digital trading platform for home care organisations and
Slide 23: Wholesale: Leader in wholesale distribution
About Galenica Market environment Business performance Governance Sustainability Outlook Wholesale: Leader in wholesale distribution Key takeaways Wholesale market share1 − Wide product range with around 100,000 % pharmacy channel Galenica products in pharma, non-pharma, (to own 25.2 pharmacies) pra
Slide 24: Wholesale: Leader in wholesale distribution
About Galenica Market environment Business performance Governance Sustainability Outlook Wholesale: Leader1) in wholesale distribution Wholesale distribution with four distribution centers: Customers by channel Pharmacies ~ 1,250 Drugstore ~ 250 Medical practices > 5,600 Hospitals/Nursing homes > 50
Slide 25: Logistics & IT Services: Leader in pre-wholesale distribution
About Galenica Market environment Business performance Governance Sustainability Outlook Logistics & IT Services: Leader in pre-wholesale distribution Key takeaways Warehouse capacity − Third-party logistics provider for the pharmaceutical industry 35,200 m2 (pre-wholesaling) including additional se
Slide 26: Logistics & IT Services: Strong IT competencies
About Galenica Market environment Business performance Governance Sustainability Outlook Logistics & IT Services: Strong IT competencies to drive digital transformation Key takeaways Internal IT Services Market offering − Agile Software Development and Projects for Galenica pharmacies und Logistic p
Slide 27: Logistics & IT Services: Patient safety, convenience and efficiency
About Galenica Market environment Business performance Governance Sustainability Outlook Logistics & IT Services: Our approach towards more patient safety, convenience and efficiency Medication Master Data Diagnosis Clinical Decision Support (CDS) Anamnesis Prescription Patients on-/offline e-Prescr
Slide 28: Market environment
Market environment Galenica – Health and wellbeing are at the heart of what we do.
Slide 29: Swiss healthcare market: resilient and stable growth
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market Proven track record of resilient and stable growth Development of Swiss healthcare retail sector1 in billion CHF (based on ex-manufacturer price) 2023-26 CAGR 2.0%3 6 2012-22 CAGR 2.7%2 5
Slide 30: Swiss pharmaceutical market: Development by channel 2022
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss pharmaceutical market: Development by channel 2022 Value (ex-factory): CHF 7‘030.3 million Volume (packs): 199.1 million CHF +406.4 million / +6.1% +17.2 million / +9.5% Pharmacies 8.2% Pharmacies 3’423.2
Slide 31: Swiss pharmaceutical market: monthly development 2019-2022
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss pharmaceutical market: monthly development 2019 - 2022 Strong sales development in 2022 value (ex-factory) in million CHF Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D Medicines Swissmedic lists A
Slide 32: Galenica as key driver of generic substitution
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss pharmaceutical market: Galenica as key driver of generic substitution in the Swiss pharmacy channel Drugs reimbursable by health insurance Patent protected products Substitution rate market3 4.8 million, +
Slide 33: Consumer healthcare market: Normalisation of OTC sales in 2022
About Galenica Market environment Business performance Governance Sustainability Outlook Consumer healthcare market: Normalisation of sales of OTC medications in 2022 Consumer healthcare market 2022 (w/o COVID-19 self-tests) OTC OTC overall 3.2% market +9.5% +9.5% 12.1% Personal care Cough remedies
Slide 34: Swiss Healthcare Market: Regulatory environment
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss Healthcare Market: Regulatory environment Topic / Initiative Current status Reduction in drug − Standard process, FOPH verifies drug prices in a three-year cycle prices − Price reduction round for 2021 com
Slide 35: Regulatory environment: Constant pressure on drug prices
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment Constant pressure on drug prices Annual savings per channel at public and ex-factory price in million CHF Price reduction rounds 140.0 Pharmacies Physicians Hospit
Slide 36: Current composition of drug prices (SBR IV)
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment Current composition of drug prices (SBR IV) Fixed margin elements help to offset price reductions Composition of the price of a prescription/ reimbursable drug: c.
Slide 37: Proposal of SBR V contract and distribution margin model
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment Proposal of SBR V contract and distribution margin model Price-related surcharge = 3% Surcharge per pack = CHF 9.45 SBR IV SBR V Product margin cap = CHF 300.– ser
Slide 38: New proposal for distribution margin
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment New proposal for distribution margin The new proposal by the FOPH includes an adjustment of the distribution margin model with uniform margin for medications with
Slide 39: Megatrends and their impact on Galenica
About Galenica Market environment Business performance Governance Sustainability Outlook Megatrends and their impact on Galenica Changing customer needs Digitalisation Ageing society We further improve the customer experience We want to play a leading role in the Our strategic focus includes service
Slide 40: Business performance
Our success story Business performance Galenica – Health and wellbeing are at the heart of what we do.
Slide 41: Key business events 2022
About Galenica Market environment Business performance Governance Sustainability Outlook Key business events 2022 November 2022: July 2022: Galenica June 2022: June 2022: Verfora Galenica acquires acquired 100% of Galenica joined will take over the the Swiss pioneer March 2022: the shares in the dig
Slide 42: Performance overview: History of resilient growth and margin improvement
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group History of resilient growth and margin improvement Logistics, HealthCare Galenica Information & Retail1 2012 – 2021 CAGRs Retail market sales2 2.7% Galenica net sales 4.1% Gal
Slide 43: Strong performance development in both segments
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Strong performance development in both segments Products & Care Logistics & IT Retail Products & Care1 Logistics and HCI Logistics & IT1 3.4% 5.2% 0.7% 3.9% Net sales (CHFm) 2
Slide 44: Strong sales and EBIT growth
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Strong sales and EBIT growth Net sales (in million CHF) Adjusted2) EBIT (in million CHF) ROS (in %) +5.5% -1.4% ’96 5.6% ’ 57 +4.2% 101.4 100.0 -0.5% H1 2021 ’ 7 ’ 5 H1 2021 5
Slide 45: Adjusted consolidated statement of income
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Adjusted consolidated statement of income1 Key developments in million CHF H1 2022 H1 2021 in % Net sales ’96 ’ 57 +5.5% Strong net sales growth of 5.5% Cost of goods -1’468 -
Slide 46: Solid balance sheet with strong equity ratio
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Solid balance sheet with strong equity ratio Key developments in million CHF ’ 6 ’ ’ 5 S d ’ q y y Shareholders’ equity slightly lower than Dec 2021 adjusted 1) despite divide
Slide 47: Condensed balance sheet
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Condensed balance sheet Key developments in million CHF H1 2022 2021 Change Cash and cash equivalents 21 165 -144 Increase of trade receivables due to seasonality effect Trade
Slide 48: Investments
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Investments in million CHF 60.4 Investment focus 18.2 Intangible assets: − SAP implementation at Alloga/Galexis Investments in 42.2 intangible assets 30.8 − digital Omni-chann
Slide 49: Solid operating cash flow
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Solid operating cash flow Key developments in million CHF H1 2022 H1 2021 Change Cash flow from operating activities before Strong increase of net 134.8 138.7 -3.9 working cap
Slide 50: Sales growth in all business areas
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Sales growth in all business areas Strong sales Net sales (in million CHF) H1 2022 H1 2021 change growth of OTC Local Pharmacies 628 617 +1.8% medications Pharmacies at Home 2
Slide 51: Local Pharmacies: growth in line with market development
About Galenica Market environment Business performance Governance Sustainability Outlook Local Pharmacies: growth in line with market development Net sales (in million CHF) Key developments High demand for cough and cold medications +1.8% 1’262 Increasing footfall at 617 628 high-frequency locations
Slide 52: Local Pharmacies: high frequency locations almost back to normal
About Galenica Market environment Business performance Governance Sustainability Outlook Local Pharmacies: high frequency locations almost back to normal Net sales development of high frequency locations compared to pre-pandemic level 1) (indexed, Jan 2019 = 100%) January 2022: 26% below pre- Dec 20
Slide 53: Pharmacies at home: continued strong growth
About Galenica Market environment Business performance Governance Sustainability Outlook Pharmacies at home: continued strong growth Net sales (in million CHF) Key developments Growth related to sales in the area of rare diseases +16.1% +16.2% 459 Continued growth of Bichsel HomeCare 218 253 Service
Slide 54: Products & Brands: exceptionally strong sales growth
About Galenica Market environment Business performance Governance Sustainability Outlook Products & Brands: exceptionally strong sales growth Net sales (in million CHF) Key growth drivers 132 +26.0% High demand for cough and cold medications & 27 travel-related International 75 products 60 Swiss 13
Slide 55: Services for professionals: strong sales growth due to expansion
About Galenica Market environment Business performance Governance Sustainability Outlook Services for professionals: strong sales growth due to expansion Net sales (in million CHF) Key developments Acquisition of Lifestage Solutions +18.3% AG in H2 2021 62 Strong growth of ~10% at Medifilm 29 34 and
Slide 56: Wholesale: pleasing sales growth
About Galenica Market environment Business performance Governance Sustainability Outlook Wholesale: pleasing sales growth Net sales (in million CHF) Key developments Adjusted growth1) in ’7 physician segment +3.8% +8.4% 761 Physicians ’ 9 ’ 79 Growth in pharmacies Pharmacies segment (without COVID-
Slide 57: Logistics & IT services
About Galenica Market environment Business performance Governance Sustainability Outlook Logistics & IT services Net sales (in million CHF) Key growth drivers Change in the billing of group-internal IT services in H2 2021 +26.2% due to the new organisation structure 112 64 Sales growth with the 51 e
Slide 58: Share information: History of share price since IPO
About Galenica Market environment Business performance Governance Sustainability Outlook Share information History of share price since IPO IPO offer price CHF 39.00 Initial trade price 7 April 2017 CHF 43.00 Share price 30 June 2022 CHF 73.30 18/01/23 58
Slide 59: Historical dividend per share and dividend yield
About Galenica Market environment Business performance Governance Sustainability Outlook Share information Historical dividend per share and dividend yield1 3.9% Dividend guidance: • 50% of dividend payout 3.3% from reserves from 3.0% 3.1% 3.1% capital contributions (exempt from WHT) • Dividend outl
Slide 60: Share information: Key figures
About Galenica Market environment Business performance Governance Sustainability Outlook Share information Key figures in CHF Jun 2022 Dec 2021 Share price at reporting date 73.30 68.55 Highest share price for the period 74.85 73.15 Lowest share price for the period 62.35 57.20 Market capitalisation
Slide 61: Governance
Governance Galenica – Health and wellbeing are at the heart of what we do.
Slide 62: Shareholder structure
About Galenica Market environment Business performance Governance Sustainability Outlook Shareholder structure Major shareholders (31 Dec 2021) Proportion of shareholders by country (Dec 2021) − Shareholders over 3%: in % 1% Number of Shareholders Shares in % shares UBS Fund Management 31% Switzerla
Slide 63: Overview of our governance structure and instruments
About Galenica Market environment Business performance Governance Sustainability Outlook Overview of our governance structure and instruments Annual General Meeting External advisory and inspection bodies / auditors Board of Directors Audit and Remuneration Governance, Nomination and Sustainability
Slide 64: Board of Directors
About Galenica Market environment Business performance Governance Sustainability Outlook Board of Directors Daniela − Elected since 2017 Prof. − Elected since 2017 Bosshardt − Pharmacist, Federal Diploma in Pharmacy, Hon. − Swiss-registered Doctor of Internal Medicine and Chairwoman Federal Institut
Slide 65: Board of Directors: Committees and competencies
About Galenica Market environment Business performance Governance Sustainability Outlook Board of Directors Committees and competencies ARC (Audit and Risk Members: Markus Neuhaus (Chairman), Budget / medium-term planning Bertrand Jungo, Andreas Walde, Judith Committee) Meier Risk management Complia
Slide 66: Board of Directors: Competencies and diversity
About Galenica Market environment Business performance Governance Sustainability Outlook Board of Directors Competencies and diversity Competencies Age of BoD members (Jun 2022) 14% 15% 40 - 45 Bosshardt Bruderer Burnier Jungo Meier Neuhaus Walde Daniela Pascale Michel Bertrand Judith Markus Andreas
Slide 67: Management structure Galenica Group
About Galenica Market environment Business performance Governance Sustainability Outlook Management structure Galenica Group 1) Pharmacies* Healthcare* Products & Marketing* Wholecare & Logistics* IT & Digital Services* Virginie Pache Jeschka Daniela Madonna Thomas Szuran Andreas Koch Lukas Ackerman
Slide 68: Executive Committee
About Galenica Market environment Business performance Governance Sustainability Outlook Executive Committee Marc Werner − CEO since 2020 Thomas − Chief Products & Marketing Officer since 2021 CEO − 25 years industry experience Szuran − 25 years industry experience of which 3 years − Joined Galenica
Slide 69: Remuneration
About Galenica Market environment Business performance Governance Sustainability Outlook Remuneration Responsibility for the remuneration process Level of authority CEO Remuneration Committee Board of Directors Annual General Meeting consultative vote on the Remuneration policy proposes approves Rem
Slide 70: Remuneration
About Galenica Market environment Business performance Governance Sustainability Outlook Remuneration Remuneration components STI LTI − The remuneration components of the Corporate Executive 25% individual 50% Committee (EC) consists of a fixed compensation, benefits and objectives average a variabl
Slide 71: Sustainability
Sustainability Galenica – Health and wellbeing are at the heart of what we do.
Slide 72: Sustainability at Galenica: Overview
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Overview Sustainability guidelines Enterprise value Employees Resource efficiency Long-term increase in the value of Commitment of employees to act The respectful and efficient use of
Slide 73: Matrix of the main topics
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Matrix of the main topics 18/01/23 73
Slide 74: Our focus areas for sustainable business practice
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our focus areas for sustainable business practice Corporate governance Patients − Ethical and legal business activities − Increase patient safety and health − Protect patient data and
Slide 75: Our sustainability goals: Corporate governance
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Corporate governance Performance 2021 Ethical and legal business activities We train all employees in compliance at least once a year. IT security trainings in
Slide 76: Our sustainability goals: Patients
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Patients Performance 2021 Increase patient safety and health − We will expand the use of the e-Mediplan in Galenica Average availability of Amount of Primary C
Slide 77: Our sustainability goals: Environment
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Performance 2021 Environment Reduce and safely dispose of waste We will reduce our municipal waste by 50% by 2025. Minimise greenhouse gas emissions − From 202
Slide 78: Our sustainability goals: Employees
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Employees Performance 2021 Promote employee motivation and development Employee motivation rate We will increase the motivation rate of our employee survey to
Slide 79: ESG Ratings
About Galenica Market environment Business performance Governance Sustainability Outlook ESG Ratings Rating-Agentur Rating 2021 / 2022 Percentile Comment ESG Risk Top 2% (Global Universe) − Ranking number 5 among 605 Healthcare companies (Rating score: 12.0) − Very good scores in Business ethics, Da
Slide 80: Outlook
Outlook Galenica – Health and wellbeing are at the heart of what we do.
Slide 81: Outlook Products & Care
About Galenica Market environment Business performance Governance Sustainability Outlook Outlook Products & Care Winconcept will Intensify Expansion of the launch a new “Primary Care” collaboration Continuous new Sun Store partnership module from between Bichsel, optimisation and store concept to mo
Slide 82: Outlook Logistics & IT
About Galenica Market environment Business performance Governance Sustainability Outlook Outlook Logistics & IT Implementation of Galexis: measures to achieve the sustainability goals Alloga: − Roll-out of the new ERP is a top priority “E-prescription” pilot system to be driven Launch of the new ERP
Slide 83: Updated EBIT and Dividend guidance 2022
About Galenica Market environment Business performance Governance Sustainability Outlook Updated EBIT and Dividend guidance 2022 → EBIT guidance as communicated with HY results: adjusted EBIT (excluding the effects IAS19 & IFRS16) +8% to +12%, excluding the extraordinary results from the COVID-19 in
Slide 84: Mid-term guidance
About Galenica Market environment Business performance Governance Sustainability Outlook Mid-term guidance − Thanks to − consistent implementation of the strategic programmes and − further expansion and optimisation of the pharmacy network and the Verfora product portfolio, − Galenica plans to grow
Slide 85: Reasons to invest in Galenica
About Galenica Market environment Business performance Governance Sustainability Outlook Reasons to invest in Galenica Unique combination of defensive resilience and significant growth … Defensive resilience History of growth Strategic focus 1. Stable and attractive Swiss 3. Significant operational
Slide 86: Contact information Investor Relations
About Galenica Market environment Business performance Governance Sustainability Outlook Galenica Group - Contact information Investor Relations Felix Burkhard CFO Tel.: +41 58 852 85 31 Julian Fiessinger Head of Investor Relations and Corporate Finance Tel.: +41 58 852 85 37 Mail: investors@galenic
Slide 87: Disclaimer
About Galenica Market environment Business performance Governance Sustainability Outlook Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and